Mid-Cap / Micro-Cap Top Movers of the Week |
Momentum Movers |
This week’s board mixed AI infrastructure strength with two healthcare breakouts and one split-adjusted optical illusion. |
$ERAS ( ▲ 2.91% ) : Erasca, jumped 16 spots to #4: This week’s top dawg added +2.9% and extended its YTD run to +394.1%. July’s Phase 1 update showed a 57% unconfirmed response rate for ERAS-0015 in pancreatic cancer. Risk:The data remain early, and the next major update is not expected until H1 2027. |
$ATEX ( ▲ 0.04% ) : Anterix, jumped 15 spots to #8: The ranking leap looked louder than the stock, which finished flat WTD after fiscal Q1 results. Its $250M repurchase authorization remains the capital-return hook. Risk: Fiscal 2026 spectrum revenue was only $6.5M, leaving the valuation dependent on slow-moving utility agreements. |
$BYND ( ▲ 10.32% ) : Beyond Meat, new at #1: The +10.3% week and +1,542.7% YTD figure came with a giant asterisk after a 1-for-30 reverse split. Q2 revenue fell 8.2% to $68.8M, while adjusted EBITDA remained negative at $27.7M. Risk: A smaller share count does not repair shrinking sales. |
$ETON ( ▲ 44.27% ) : Eton Pharmaceuticals, new at #17: Shares exploded +44.3% after Q2 revenue doubled to $37.6M and management raised 2026 guidance above $145M. Risk:Friday priced in a clean September IMPAVIDO launch and continued HEMANGEOL conversions. |
$AAOI ( ▲ 15.53% ) : Applied Optoelectronics, slipped one spot to #7: The stock still gained +15.5% as strong Q2 results reinforced the AI-optics demand story. Its 23.6k watchers made it the board’s loudest infrastructure name. Risk: A small number of hyperscale customers still controls a substantial share of orders. |
Next week’s swing factor: The Fed’s July meeting minutes arrive Aug. 19. A hawkish read pressures both early-stage biotech valuations and premium AI infrastructure names. |
